Clinical investigator financial disclosure final rule sets $25,000 payment, $50,000 equity threshold.
This article was originally published in The Gray Sheet
FINANCIAL DISCLOSURE THRESHOLD FOR CLINICAL INVESTIGATORS RAISED TO $25,000 in a final rule published by FDA in the Feb. 2 Federal Register. In its 1994 proposal, the agency had suggested a significantly lower trigger of $5,000 ("The Gray Sheet" Sept. 26, 1994, p. 12).
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.